MILPITAS, Calif. -
March 13, 2018 -
PRLog -- Arginase (EC 3.5.3.1) is a manganese-containing enzyme which catalyzes the conversion of arginine into urea and ornithine, which is the final reaction in the urea cycle. Arginase I (ARG1) is the liver isoform of arginase. Recent studies showed that ARG1 expression by mature myeloid cells in tumor environment as demonstrated in a 3LL murine lung carcinoma model causes L-Arginine depletion by tumor-associated myeloid cells (TAMC). L-arginine depletion suppresses immune-response against tumor cells due to inhibition to T-cell proliferation. In addition, the depletion of arginine increases the reactive nitrogen species (NOS) and reactive oxygen species (ROS), which, in consequence, induce T-cell apoptosis and supports antigenic cell proliferation. BioVision's Arginase I (ARG1) Inhibitor Screening Kit is designed for screening ARG1 inhibitors. Two substituted-
2-amino-6-hexanoic acids have been studied as arginase inhibitor and in this kit, Amino-2-Borono-
6-Hexanoic Acid (ABH) is provided as a positive control. The ARG1 activity is monitored by the increase in absorbance readings (OD 450 nm), while potential inhibitors will cause a decrease of absorbance. The assay kit is simple, quick and can be used to identify and characterize ARG1 inhibitors in a high-throughput format.
Figure: Inhibition of arginase I enzymatic activity by Amino-2-Borono-
6-Hexanoic Acid (ABH). IC
50 of ABH was determined to be 1.39 ±0.10µM. Assay was performed following the kit protocols.
For detailed information on this product, visit:
https://www.biovision.com/arginase-i-arg1-inhibitor-scree...
